FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs
Fc receptors (FcR) play a key role in coordinating responses from both the innate and adaptive immune system. The inhibitory Fc gamma receptor (FcγRIIB/CD32B; referred to as FcγRII/CD32 in mice) restrains the immune response, specifically through regulating immunoglobulin G (IgG) effector functions. FcγRII-deficient mice demonstrate elevated incidence and severity of autoimmunity and increased responses to immunization and infections. To explore the potential of FcγRIIB as a target for augmenting vaccines, we tested the ability of monoclonal antibodies (mAb) against mouse FcγRII and human FcγRIIB to enhance humoral responses in preclinical models. We used wild-type (WT), FcγR-deficient, and human FcγRIIB transgenic (Tg) mice with either a functional intracellular domain (hFcγRIIB Tg) or lacking immunoreceptor tyrosine-based inhibitory motif (ITIM) signalling capacity (NoTIM). Targeting mouse FcγRII and human FcγRIIB with antibodies significantly augmented humoral immune responses against experimental antigens and enhanced tumour clearance in vivo. Surprisingly, mAbs without a functional Fc (N297Q; referred to as Fc-null) lacked efficacy. Similarly, blocking FcγRII in mice lacking activating FcγRs failed to enhance immune responses. Conversely, blocking both signalling-competent and signalling-defective (NoTIM) FcγRIIB in Tg mice with a WT, but not Fc-null, FcγRIIB mAb equally enhanced immunity. These data indicate the redundancy of inhibitory signalling in potentiating immune responses in vivo. Collectively, our data suggest that mAb-targeting of FcγRIIB stabilizes mAb Fc and enhances immune responses via Fc-mediated crosslinking of activating FcγRs, irrespective of the inhibitory function of FcγRIIB. These findings support a strategy to boost immune responses in immunization protocols.
Simpson, Alexander P.
04bf12e8-6eb1-4135-9db0-d521d4a58dd7
Oldham, Robert J.
844b9bff-16f0-4577-abba-b35afd02b923
Cox, Kerry L.
7305c27e-9cdc-4e37-b994-ac55d7d1dfd2
Taylor, Martin C.
9e6d2e6d-5e00-4610-8ec6-5f117296124a
James, Sonya
764c80e3-5bea-4b34-a871-b43f87ef97b0
Bogdanov, Yury
0c970999-e191-4f1b-90d9-7bf25a5d5b4b
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Frendeus, Bjorn
3c6a6739-3319-4ae5-8019-d54470e2f444
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
2 May 2025
Simpson, Alexander P.
04bf12e8-6eb1-4135-9db0-d521d4a58dd7
Oldham, Robert J.
844b9bff-16f0-4577-abba-b35afd02b923
Cox, Kerry L.
7305c27e-9cdc-4e37-b994-ac55d7d1dfd2
Taylor, Martin C.
9e6d2e6d-5e00-4610-8ec6-5f117296124a
James, Sonya
764c80e3-5bea-4b34-a871-b43f87ef97b0
Bogdanov, Yury
0c970999-e191-4f1b-90d9-7bf25a5d5b4b
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Frendeus, Bjorn
3c6a6739-3319-4ae5-8019-d54470e2f444
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
Simpson, Alexander P., Oldham, Robert J., Cox, Kerry L., Taylor, Martin C., James, Sonya, Bogdanov, Yury, Glennie, Martin J., Frendeus, Bjorn, Cragg, Mark S. and Roghanian, Ali
(2025)
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.
Clinical and Experimental Immunology, 219 (1), [uxaf015].
(doi:10.1093/cei/uxaf015).
Abstract
Fc receptors (FcR) play a key role in coordinating responses from both the innate and adaptive immune system. The inhibitory Fc gamma receptor (FcγRIIB/CD32B; referred to as FcγRII/CD32 in mice) restrains the immune response, specifically through regulating immunoglobulin G (IgG) effector functions. FcγRII-deficient mice demonstrate elevated incidence and severity of autoimmunity and increased responses to immunization and infections. To explore the potential of FcγRIIB as a target for augmenting vaccines, we tested the ability of monoclonal antibodies (mAb) against mouse FcγRII and human FcγRIIB to enhance humoral responses in preclinical models. We used wild-type (WT), FcγR-deficient, and human FcγRIIB transgenic (Tg) mice with either a functional intracellular domain (hFcγRIIB Tg) or lacking immunoreceptor tyrosine-based inhibitory motif (ITIM) signalling capacity (NoTIM). Targeting mouse FcγRII and human FcγRIIB with antibodies significantly augmented humoral immune responses against experimental antigens and enhanced tumour clearance in vivo. Surprisingly, mAbs without a functional Fc (N297Q; referred to as Fc-null) lacked efficacy. Similarly, blocking FcγRII in mice lacking activating FcγRs failed to enhance immune responses. Conversely, blocking both signalling-competent and signalling-defective (NoTIM) FcγRIIB in Tg mice with a WT, but not Fc-null, FcγRIIB mAb equally enhanced immunity. These data indicate the redundancy of inhibitory signalling in potentiating immune responses in vivo. Collectively, our data suggest that mAb-targeting of FcγRIIB stabilizes mAb Fc and enhances immune responses via Fc-mediated crosslinking of activating FcγRs, irrespective of the inhibitory function of FcγRIIB. These findings support a strategy to boost immune responses in immunization protocols.
Text
uxaf015
- Version of Record
More information
Accepted/In Press date: 11 March 2025
e-pub ahead of print date: 16 March 2025
Published date: 2 May 2025
Identifiers
Local EPrints ID: 502084
URI: http://eprints.soton.ac.uk/id/eprint/502084
ISSN: 0009-9104
PURE UUID: 39387474-10c2-425a-941b-b9fc36700676
Catalogue record
Date deposited: 16 Jun 2025 16:46
Last modified: 04 Sep 2025 02:09
Export record
Altmetrics
Contributors
Author:
Alexander P. Simpson
Author:
Robert J. Oldham
Author:
Kerry L. Cox
Author:
Martin C. Taylor
Author:
Sonya James
Author:
Bjorn Frendeus
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics